These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 36345240)
1. Construction of IMMS Containing Multi-site Liposomes for Dynamic Monitoring of Blood CTC in Patients with Osimertinib-resistant Non-small-cell Lung Cancer and its Mechanism. Chen X; Luo L; Lu Y; Qiu Y; Liang J; Chen Y; Ning Y; Li B Anticancer Agents Med Chem; 2023; 23(6):676-686. PubMed ID: 36345240 [TBL] [Abstract][Full Text] [Related]
2. Real-world data on treatment outcomes in Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036 [TBL] [Abstract][Full Text] [Related]
3. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation. Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670 [TBL] [Abstract][Full Text] [Related]
4. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754 [TBL] [Abstract][Full Text] [Related]
5. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition. Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097 [TBL] [Abstract][Full Text] [Related]
6. Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer. Isobe K; Yoshizawa T; Sekiya M; Miyoshi S; Nakamura Y; Urabe N; Isshiki T; Sakamoto S; Takai Y; Tomida T; Adachi-Akahane S; Iyoda A; Homma S; Kishi K Respir Investig; 2021 Jul; 59(4):535-544. PubMed ID: 33934994 [TBL] [Abstract][Full Text] [Related]
7. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310 [TBL] [Abstract][Full Text] [Related]
8. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931 [TBL] [Abstract][Full Text] [Related]
9. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer. Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353 [TBL] [Abstract][Full Text] [Related]
10. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib. Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539 [TBL] [Abstract][Full Text] [Related]
11. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198 [TBL] [Abstract][Full Text] [Related]
12. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260 [TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor-targeted immunomagnetic liposomes for circulating tumor cell enumeration in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors. Cui S; Ni Y; Zhao Y; Li Z; Xiong L; Liu J; Liang X; Jiang L Lung Cancer; 2019 Jun; 132():45-53. PubMed ID: 31097093 [TBL] [Abstract][Full Text] [Related]
14. Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient. Yang Z; Yang J; Chen Y; Shao YW; Wang X Target Oncol; 2019 Aug; 14(4):369-374. PubMed ID: 31301016 [TBL] [Abstract][Full Text] [Related]
15. Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer. Wu S; Luo M; To KKW; Zhang J; Su C; Zhang H; An S; Wang F; Chen D; Fu L Mol Cancer; 2021 Jan; 20(1):17. PubMed ID: 33461557 [TBL] [Abstract][Full Text] [Related]
16. Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator). Tamiya A; Isa SI; Taniguchi Y; Nakagawa H; Atagi S; Ando M; Koh Y Clin Lung Cancer; 2021 May; 22(3):e336-e341. PubMed ID: 32641247 [TBL] [Abstract][Full Text] [Related]
17. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib. Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501 [TBL] [Abstract][Full Text] [Related]
18. Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer. Chen W; Yu D; Sun SY; Li F Acta Biomater; 2021 Jul; 129():258-268. PubMed ID: 34048974 [TBL] [Abstract][Full Text] [Related]
19. When compared to plasma-based detection, osimertinib-treated non-small cell lung cancer (NSCLC) with tissue rebiopsy-confirmed acquired T790M mutation is associated with better survival. Kwok WC; Ho JCM; Lam DCL; Lui MMS; Ip MSM; Tam TCC Asia Pac J Clin Oncol; 2021 Apr; 17(2):e35-e39. PubMed ID: 31802642 [TBL] [Abstract][Full Text] [Related]